<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952599</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-D-A4010</org_study_id>
    <nct_id>NCT02952599</nct_id>
  </id_info>
  <brief_title>Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)</brief_title>
  <official_title>Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism (VTE) in Korea and Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to current guidelines, duration of anticoagulant treatment after a venous
      thromboembolic event varies from 3 months to indefinite treatment depending on the estimated
      risks of venous thromboembolism (VTE) recurrence and bleeding. Current data for edoxaban are
      limited to a maximum treatment duration of 12 months.

      Therefore, this study aims to gather further insight into efficacy (i.e. symptomatic
      recurrent VTE) and safety (i.e. bleeding events, liver adverse events, all-cause mortality
      and other drug related adverse events) of extended treatment with edoxaban up to 12 months in
      an unselected patient population in routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Edoxaban is an orally administered anticoagulant that inhibits coagulation factor Xa. It has
      been approved by the Ministry of Food and Drug Safety (MFDS) in Korea (date: 25th, August
      2015) for the: Reduction in the risk of stroke and systemic embolism in patients with non
      valvular atrial fibrillation (NVAF) Treatment of deep vein thrombosis (DVT) and pulmonary
      embolism (PE) Reduction in the risk of recurrent DVT and PE, and by Taiwan Food and Drug
      Administration (TFDA) in Taiwan (date: 24th, February, 2016) for the Prevention of stroke and
      systemic embolism in adult patients with NVAF with one or more risk factors, such as
      congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or
      transient ischemic attack (TIA). Treatment of deep vein thrombosis (DVT) and pulmonary
      embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.

      According to current guidelines, duration of anticoagulant treatment after a venous
      thromboembolic event varies from 3 months to indefinite treatment depending on the estimated
      risks of venous thromboembolism (VTE) recurrence and bleeding. Current data for edoxaban are
      limited to a maximum treatment duration of 12 months.

      This non-interventional study aims to gather further insight into efficacy (i.e. symptomatic
      recurrent VTE) and safety (i.e. bleeding events, liver adverse events, all-cause mortality
      and other drug related adverse events) of extended treatment with edoxaban up to 12 months in
      approximately 350 patients in an unselected patient population in routine clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of overall symptomatic VTE recurrence</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Rate of overall symptomatic VTE recurrence within 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of participants experiencing Real World Safety Data Events</measure>
    <time_frame>12 months</time_frame>
    <description>Categories: VTE-related bleeding events, Drug-related adverse events, Cardiovascular Mortality, and All-cause Mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participants taking edoxaban with symptomatic VTE recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of participants taking edoxaban with symptomatic VTE recurrence in 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants who permanently discontinued edoxaban with symptomatic VTE recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of participants who permanently discontinued edoxaban with symptomatic VTE recurrence in 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants with patient relevant outcomes</measure>
    <time_frame>12 months</time_frame>
    <description>Patient relevant outcomes include bleeding events, strokes (ischaemic and haemorrhagic), systemic embolic events (SEE), and hospitalisations related to cardiovascular (CV) condition (including VTE related hospitalisation).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Patients treated with Edoxaban</arm_group_label>
    <description>Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Prescribed according to approved label</description>
    <arm_group_label>Patients treated with Edoxaban</arm_group_label>
    <other_name>Lixiana</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with established acute initial or recurrent VTE treated with edoxaban
        according to package information. To ensure that the physician's prescribing behaviour will
        not be influenced, patients may only be included after the treating physician has made the
        clinical decision to prescribe edoxaban. Patients must have provided written informed
        consent for participation in the study (ICF) and should not participate simultaneously in
        any interventional study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established acute initial or recurrent VTE

          -  Patients prescribed treatment with edoxaban according to package information before
             participation in the trial

          -  Written informed consent for participation in the study (ICF)

          -  Not simultaneously participating in any interventional study

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SoonChunHyang University Hospital Gumi</name>
      <address>
        <city>Gyeongsang</city>
        <state>Gumi</state>
        <zip>39371</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <state>Haeundae-gu</state>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Gyeongsang</city>
        <state>Jinju-si</state>
        <zip>52727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Seogu</city>
        <state>Kwang-Jo Cho</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu</state>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SoonChunHyang University Hospital Seoul</name>
      <address>
        <city>Seoul</city>
        <state>Yongsan-gu</state>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University, Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisoo Kwon</last_name>
      <phone>+82 220540623</phone>
      <email>jisoo.kwon@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <state>Banciao District</state>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Beitou District</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, KaoHsiung</name>
      <address>
        <city>Kaohsiung</city>
        <state>Niaosong District</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Pai-Tou</state>
        <zip>11220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Shih Lin District</state>
        <zip>11101</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Zhongzheng District</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KaoHsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>Zuoying District</state>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Chang-hua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Lin</last_name>
      <phone>+886 22657777772536</phone>
      <email>melody.lin@apluscro.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.</citation>
    <PMID>23991658</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-interventional Study</keyword>
  <keyword>Real World Evidence</keyword>
  <keyword>Patients with Acute VTE treated with Edoxaban</keyword>
  <keyword>Efficacy/Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

